Skip to main content
Signal8

vVARDIS Holding AG Form 424B4 — Nov 16, 2026

Form 424B4Filed Nov 16, 2026, 6:06 AM ET0001140361-26-043938Original filing

vVARDIS Holding AG priced its IPO at $18.00 per Class A ordinary share, offering 9,722,223 shares for approximately $175.0 million in gross proceeds ($154.5 million net), with a 1,458,333-share over-allotment option. The shares will list on the NYSE under the symbol VVVV, led by Goldman Sachs and J.P. Morgan, with a 180-day lockup (270 days for the Co-Founders). The company is a Swiss oral-health company commercializing Curodont, a peptide-based drill-free treatment for early-stage cavities distributed exclusively in the U.S.

Key figures

Revenue
30209000
Guidance
Preliminary nine months ended September 30, 2026: net revenue $47.7M-$49.2M, gross profit $41.1M-$42.3M (86.0%-86.2% margin), net loss $(39.7)M-$(41.3)M, Adjusted EBITDA $(9.2)M-$(9.4)M
Revenue Yoy
148.5% for FY2025; 214.2% for the six months ended June 30, 2026; 114.0%-120.8% expected for the nine months ended September 30, 2026
Total Assets
104803000
Cash Position
$28,974 thousand as of June 30, 2026; estimated $19.4 million as of September 30, 2026
Gross Proceeds
175000014
Offering Price
18
Shares Offered
9722223
Total Debt
Total liabilities of $164.4 million as of June 30, 2026
Net Proceeds
$154.5 million (approximately $178.9 million with over-allotment in full)
Greenshoe Shares
1458333
Fy2025 Gross Margin
74.2%
Accumulated Deficit
$256.3 million as of June 30, 2026
Founder Voting Power
86.9%
H1 2026 Gross Margin
86.4%
Recurring Buying Practices
11,158 as of Q3 2026
Underwriting Discount Per Share
1.26

AI analysis

Red flags7 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.